Connection

Francis Spinale to Female

Back to Details
This is a "connection" page, showing publications Francis Spinale has written about Female.
Francis Spinale
Connection Strength
0.861
Female
  1. Ubiquitin ligase Wwp1 gene deletion attenuates diastolic dysfunction in pressure-overload hypertrophy. Am J Physiol Heart Circ Physiol. 2021 11 01; 321(5):H976-H984.
    View in: PubMed
    Score: 0.041
  2. Cytokine Signaling and Matrix Remodeling Pathways Associated with Cardiac Sarcoidosis Disease Activity Defined Using FDG PET Imaging. Int Heart J. 2021 Sep 30; 62(5):1096-1105.
    View in: PubMed
    Score: 0.041
  3. The ubiquitin ligase WWP1 contributes to shifts in matrix proteolytic profiles and a myocardial aging phenotype with diastolic heart. Am J Physiol Heart Circ Physiol. 2020 10 01; 319(4):H765-H774.
    View in: PubMed
    Score: 0.038
  4. Common pathways and communication between the brain and heart: connecting post-traumatic stress disorder and heart failure. Stress. 2019 09; 22(5):530-547.
    View in: PubMed
    Score: 0.035
  5. Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm. 2019 05; 16(5):743-753.
    View in: PubMed
    Score: 0.034
  6. Identification of a novel microRNA profile in pediatric patients with cancer treated with anthracycline chemotherapy. Am J Physiol Heart Circ Physiol. 2018 11 01; 315(5):H1443-H1452.
    View in: PubMed
    Score: 0.033
  7. Fate Versus Flow: Wall Shear Stress in the Aortopathy Associated With Bicuspid Aortic Valves. J Am Coll Cardiol. 2015 Aug 25; 66(8):901-4.
    View in: PubMed
    Score: 0.027
  8. Preoperative steroid treatment does not improve markers of inflammation after cardiac surgery in neonates: results from a randomized trial. J Thorac Cardiovasc Surg. 2014 Mar; 147(3):902-8.
    View in: PubMed
    Score: 0.023
  9. Epilysin (matrix metalloproteinase-28) joins the matrix metalloproteinase team on the field of postmyocardial infarction remodeling. Circ Res. 2013 Feb 15; 112(4):579-82.
    View in: PubMed
    Score: 0.023
  10. Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. J Card Fail. 2012 Jun; 18(6):487-92.
    View in: PubMed
    Score: 0.022
  11. Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2012 May; 143(5):1069-76.
    View in: PubMed
    Score: 0.021
  12. Diversity of myocardial interstitial proteolytic pathways: gene deletion reveals unexpected consequences. Circulation. 2011 Nov 08; 124(19):2052-5.
    View in: PubMed
    Score: 0.021
  13. Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet. 2011 Dec; 4(6):614-9.
    View in: PubMed
    Score: 0.021
  14. Early postoperative outcomes and blood product utilization in adult cardiac surgery: the post-aprotinin era. Circulation. 2011 Sep 13; 124(11 Suppl):S62-9.
    View in: PubMed
    Score: 0.021
  15. Standardized preoperative corticosteroid treatment in neonates undergoing cardiac surgery: results from a randomized trial. J Thorac Cardiovasc Surg. 2011 Dec; 142(6):1523-9.
    View in: PubMed
    Score: 0.020
  16. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail. 2011 May; 4(3):246-56.
    View in: PubMed
    Score: 0.020
  17. Myocardial remodeling: cellular and extracellular events and targets. Annu Rev Physiol. 2011; 73:47-68.
    View in: PubMed
    Score: 0.020
  18. Determinants of extracellular matrix remodelling are differentially expressed in paediatric and adult dilated cardiomyopathy. Eur J Heart Fail. 2011 Mar; 13(3):271-7.
    View in: PubMed
    Score: 0.019
  19. Discordant activation of gene promoters for matrix metalloproteinases and tissue inhibitors of the metalloproteinases following myocardial infarction. J Surg Res. 2012 Jan; 172(1):59-67.
    View in: PubMed
    Score: 0.019
  20. Circulating matrix metalloproteinase levels after ventricular septal defect repair in infants. J Thorac Cardiovasc Surg. 2010 Dec; 140(6):1257-65.
    View in: PubMed
    Score: 0.019
  21. Effects of aprotinin or tranexamic acid on proteolytic/cytokine profiles in infants after cardiac surgery. Ann Thorac Surg. 2010 Jun; 89(6):1843-52; discussion 1852.
    View in: PubMed
    Score: 0.019
  22. Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics. J Thorac Cardiovasc Surg. 2010 Mar; 139(3):646-54.
    View in: PubMed
    Score: 0.018
  23. Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation. 2009 Sep 15; 120(11 Suppl):S220-9.
    View in: PubMed
    Score: 0.018
  24. Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. Ann Thorac Surg. 2008 Oct; 86(4):1268-76.
    View in: PubMed
    Score: 0.017
  25. Differential effects of epsilon-aminocaproic acid and aprotinin on matrix metalloproteinase release in patients following cardiopulmonary bypass. J Cardiovasc Pharmacol. 2008 Apr; 51(4):418-23.
    View in: PubMed
    Score: 0.016
  26. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation. 2006 Sep 05; 114(10):1020-7.
    View in: PubMed
    Score: 0.014
  27. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg. 2006 Mar; 131(3):679-85.
    View in: PubMed
    Score: 0.014
  28. Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail. 2005 Mar; 11(2):124-30.
    View in: PubMed
    Score: 0.013
  29. Dynamic and differential changes in myocardial and plasma endothelin in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005 Mar; 129(3):584-90.
    View in: PubMed
    Score: 0.013
  30. Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res. 2005 May 01; 66(2):410-9.
    View in: PubMed
    Score: 0.013
  31. Effects of deletion of the tissue inhibitor of matrix metalloproteinases-1 gene on the progression of murine thoracic aortic aneurysms. Circulation. 2004 Sep 14; 110(11 Suppl 1):II268-73.
    View in: PubMed
    Score: 0.013
  32. The effects of leukocyte reduction on matrix metalloproteinase release in cardiopulmonary bypass. J Extra Corpor Technol. 2004 Jun; 36(2):185-90.
    View in: PubMed
    Score: 0.012
  33. A prospective, randomized study of endothelin and postoperative recovery in off-pump versus conventional coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 2004 Feb; 18(1):25-9.
    View in: PubMed
    Score: 0.012
  34. A murine model of thoracic aortic aneurysms. J Surg Res. 2003 Nov; 115(1):157-63.
    View in: PubMed
    Score: 0.012
  35. Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2002 Dec 18; 40(12):2165-73.
    View in: PubMed
    Score: 0.011
  36. Tissue inhibitor of metalloproteinase-4 deletion in mice impacts maternal cardiac function during pregnancy and postpartum. Am J Physiol Heart Circ Physiol. 2023 01 01; 324(1):H85-H99.
    View in: PubMed
    Score: 0.011
  37. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail. 2002 Dec; 8(6):390-8.
    View in: PubMed
    Score: 0.011
  38. The Effects of Regular Exercise on Circulating Cardiovascular-related MicroRNAs. Sci Rep. 2019 05 17; 9(1):7527.
    View in: PubMed
    Score: 0.009
  39. Plasma matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs and aging and lifelong exercise adaptations in ventricular and arterial stiffness. Exp Gerontol. 2019 08; 123:36-44.
    View in: PubMed
    Score: 0.009
  40. Pulmonary artery endothelial cell phenotypic alterations in a large animal model of pulmonary arteriovenous malformations after the Glenn shunt. Ann Thorac Surg. 2013 Oct; 96(4):1442-1449.
    View in: PubMed
    Score: 0.006
  41. Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase. Pflugers Arch. 2013 May; 465(5):687-97.
    View in: PubMed
    Score: 0.006
  42. Aortic dilatation with bicuspid aortic valves: cusp fusion correlates to matrix metalloproteinases and inhibitors. Ann Thorac Surg. 2012 Feb; 93(2):457-63.
    View in: PubMed
    Score: 0.005
  43. Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. Circ Cardiovasc Genet. 2011 Dec; 4(6):605-13.
    View in: PubMed
    Score: 0.005
  44. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010 Dec 21; 122(25):2660-8.
    View in: PubMed
    Score: 0.005
  45. Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium. Histochem Cell Biol. 2010 Jul; 134(1):23-30.
    View in: PubMed
    Score: 0.005
  46. Alterations in membrane type-1 matrix metalloproteinase abundance after the induction of thoracic aortic aneurysm in a murine model. Am J Physiol Heart Circ Physiol. 2010 Jul; 299(1):H114-24.
    View in: PubMed
    Score: 0.005
  47. Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung. J Thorac Cardiovasc Surg. 2010 Apr; 139(4):984-90; discussion 990.
    View in: PubMed
    Score: 0.005
  48. Cellular phenotype transformation occurs during thoracic aortic aneurysm development. J Thorac Cardiovasc Surg. 2010 Sep; 140(3):653-9.
    View in: PubMed
    Score: 0.005
  49. Differential effects of mechanical and biological stimuli on matrix metalloproteinase promoter activation in the thoracic aorta. Circulation. 2009 Sep 15; 120(11 Suppl):S262-8.
    View in: PubMed
    Score: 0.004
  50. Alterations in aortic cellular constituents during thoracic aortic aneurysm development: myofibroblast-mediated vascular remodeling. Am J Pathol. 2009 Oct; 175(4):1746-56.
    View in: PubMed
    Score: 0.004
  51. Differential effect of wall tension on matrix metalloproteinase promoter activation in the thoracic aorta. J Surg Res. 2010 May 15; 160(2):333-9.
    View in: PubMed
    Score: 0.004
  52. Altered transforming growth factor-beta signaling in a murine model of thoracic aortic aneurysm. J Vasc Res. 2008; 45(6):457-68.
    View in: PubMed
    Score: 0.004
  53. Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. Eur J Heart Fail. 2008 Feb; 10(2):125-8.
    View in: PubMed
    Score: 0.004
  54. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail. 2007 Sep; 13(7):530-40.
    View in: PubMed
    Score: 0.004
  55. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg. 2007 Apr; 133(4):1028-36.
    View in: PubMed
    Score: 0.004
  56. Temporal disparity in the induction of matrix metalloproteinases and tissue inhibitors of metalloproteinases after thoracic aortic aneurysm formation. J Thorac Cardiovasc Surg. 2006 Oct; 132(4):788-95.
    View in: PubMed
    Score: 0.004
  57. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation. 2006 Jul 04; 114(1 Suppl):I365-70.
    View in: PubMed
    Score: 0.004
  58. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006 May 02; 113(17):2089-96.
    View in: PubMed
    Score: 0.004
  59. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation. 2005 Nov 15; 112(20):3157-67.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.